Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Current Leases (2024 - 2026)

Maze Therapeutics' Current Leases history spans 3 years, with the latest figure at $4.8 million for Q1 2026.

  • On a quarterly basis, Current Leases rose 3.51% to $4.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.8 million, a 3.51% increase, with the full-year FY2025 number at $4.8 million, up 3.52% from a year prior.
  • Current Leases hit $4.8 million in Q1 2026 for Maze Therapeutics, up from $4.8 million in the prior quarter.
  • Over the last five years, Current Leases for MAZE hit a ceiling of $4.8 million in Q1 2026 and a floor of $4.6 million in Q4 2024.
  • Historically, Current Leases has averaged $4.7 million across 3 years, with a median of $4.7 million in 2025.
  • Biggest five-year swings in Current Leases: increased 3.52% in 2025 and later rose 3.51% in 2026.
  • Tracing MAZE's Current Leases over 3 years: stood at $4.6 million in 2024, then rose by 3.52% to $4.8 million in 2025, then increased by 0.9% to $4.8 million in 2026.
  • Business Quant data shows Current Leases for MAZE at $4.8 million in Q1 2026, $4.8 million in Q4 2025, and $4.8 million in Q3 2025.